It has been a really long journey to get to this day.
We are delighted to share with you the news that the National Institute for Health Care Excellence (NICE) has recommended Lutetium (177Lu) oxodotreotide, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults.
This information is from the publicly available Final Appraisal Document (FAD). If there is no appeal to this recommendation a Final Appraisal Document will be issued by NICE as guidance, we expect this on the 29th August.
Thank you to all the patients, medical professionals and industry groups who fought so hard for this.
If you would like to read the documentation publicly available to date please click the link below and search for ID1224.
[npfButton size=“small” text=”Find out more” href=”https://www.nice.org.uk” background-colour=”#37b8c0″ text-colour=”#ffffff”]